MARKETS / COMPANIES / ECONOMYRSS edition ↗
Macro Monitor
Market News

Nasdaq-listed Amneal opens ₹135-crore Ahmedabad office, expands India footprint

SENSEX 73,123.83 -125.56 NIFTY 22,600.00 -87.65 CRUDEOIL 9,783.00 + 299.00 GOLD 142,160.00 -1,149.00 SILVER 195,900.00 -3,699.00 SENSEX 73,123.83 -125.56 NIFTY 22,600.00 -87.65 NIFTY 22,600.00 -87.65 CRUDEOIL 9,783.00 +…

Nasdaq-listed Amneal opens ₹135-crore Ahmedabad office, expands India footprint
SENSEX 73,123.83

 -125.56

NIFTY 22,600.00

 -87.65

CRUDEOIL 9,783.00

+ 299.00

GOLD 142,160.00

 -1,149.00

SILVER 195,900.00

 -3,699.00

SENSEX 73,123.83

 -125.56

NIFTY 22,600.00

 -87.65

NIFTY 22,600.00

 -87.65

CRUDEOIL 9,783.00

+ 299.00

CRUDEOIL 9,783.00

+ 299.00

GOLD 142,160.00

 -1,149.00

'; } document.getElementById("lgdv").innerHTML = htmlElements; } function numberformat(i) { return Number(parseFloat(i).toFixed(2)).toLocaleString('en', { minimumFractionDigits: 2 }) } async function gatherResponse(response) { const { headers } = response; const contentType = headers.get('content-type') || ''; if (contentType.includes('application/json')) { return await response.json() } return response.text(); } function getWidth() { if (Math.max(document.body.scrollWidth,document.documentElement.scrollWidth,document.body.offsetWidth,document.documentElement.offsetWidth,document.documentElement.clientWidth) > 991) { document.getElementById("mob").style.display = "none"; document.getElementById("lgdv").style.display = "block"; } else { document.getElementById("mob").style.display = "block"; document.getElementById("lgdv").style.display = "none"; } } getWidth(); THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

The new facility spans approximately 3.35 lakh square feet and can accommodate around 1,200 employees

By BL Ahmedabad Bureau

Updated - October 24, 2026 at 02:56 PM.

Amneal Pharmaceuticals has inaugurated a ₹135-crore administrative office in Ahmedabad. | Photo Credit: Bill Gallery

Nasdaq-listed US drugmaker Amneal Pharmaceuticals has inaugurated a ₹135-crore administrative office in Ahmedabad, expanding its corporate infrastructure in India as it strengthens its global research, development and manufacturing capabilities.

The new facility spans approximately 3.35 lakh square feet and can accommodate around 1,200 employees, stated an official release here. The investment will bring key teams together and support the company’s research and development, manufacturing and corporate functions. “This new Ahmedabad office reflects Amneal’s continued investment in the people and capabilities that support its global business. India is an important part of our network, complementing our significant and growing US manufacturing footprint,” stated Chirag Patel, co-founder and co-chief executive officer of Amneal. The new office is intended to strengthen collaboration across the company’s global operations, which span the US, India and Ireland.

The inauguration builds on Amneal’s broader investment plans for India. In October 2024, the company announced a net investment of $150 million to $200 million over four to five years to establish two greenfield manufacturing facilities in Ahmedabad — one focused on peptide synthesis and the other on advanced sterile fill-finish manufacturing.

The projects are aimed at expanding its capabilities to develop and manufacture complex medicines for India and international markets. Amneal has invested approximately $600 million in India over the past decade, according to its 2024 announcement. The company began operations in the country in 2008 and operates eight manufacturing sites, including five in Ahmedabad, with additional facilities in Dahej, Hyderabad and Visakhapatnam. It also has a commercial office in Mumbai. “Our colleagues in India play an important role in advancing Amneal’s research, development, manufacturing and business operations,” stated Chintu Patel, co-founder and co-chief executive officer.

Amneal’s global business spans complex generics, injectables, specialty medicines and biosimilars. In August 2026, the company acquired Kashiv BioSciences, further expanding its biosimilar development and manufacturing capabilities.

Published on October 24, 2026

THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.Sign into Unlock benefits!
  • Access 10 free stories per month
  • Get notified by email for early preview to new features, discounts & offers
Source: The Hindu BusinessLine — Companies ↗

Figures reflect the source report and its stated period. This article is for information and is not investment advice.